Company Filing History:
Years Active: 2025
Title: Guanying Zhang: Innovator in Monoclonal Antibody Research
Introduction
Guanying Zhang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of medical research, particularly in the development of monoclonal antibodies. His work focuses on creating solutions for serious viral infections, including Ebola.
Latest Patents
Zhang holds a patent for a monoclonal antibody known as 2G1, which is designed for broad-spectrum neutralization of Ebola viruses. The patent, titled "Monoclonal antibody 2G1 for broad-spectrum neutralization of ebola viruses and application thereof," discloses a monoclonal antibody that targets the Ebola glycoprotein GP2 subunit. This antibody exhibits binding activity to various Ebola virus glycoproteins, including EBOV GP, BDBV GP, SUDV GP, and RESTV GP, demonstrating its potential to neutralize these viruses effectively.
Career Highlights
Guanying Zhang is affiliated with the Academy of Military Medical Science, PLA, where he conducts his research. His work has been instrumental in advancing the understanding and treatment of Ebola virus infections. Zhang's innovative approach to antibody development showcases his commitment to addressing global health challenges.
Collaborations
Zhang collaborates with esteemed colleagues, including Wei Chen and Changming Yu, who contribute to his research efforts. Their combined expertise enhances the potential impact of their work in the field of viral research.
Conclusion
Guanying Zhang's contributions to monoclonal antibody research are noteworthy and reflect his dedication to improving medical science. His innovative patent for the 2G1 antibody represents a significant advancement in the fight against Ebola viruses.